A new study published in Cancer highlights significant racial and socioeconomic disparities in treatment and survival outcomes for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Black patients and those with Medicaid or no insurance were found to be less likely to receive chemotherapy and had shorter overall survival compared to white patients and those with private insurance. These findings emphasize the urgent need for targeted efforts to address healthcare inequities and improve access to life-extending treatment for all PDAC patients.
